Merck & Co. agreed to buy rival U.S. drugmaker Schering-Plough Corp. for $41.1 billion in cash and stock to get a larger experimental pipeline and products unhindered by imminent patent losses. Schering-Plough
Continue reading… which could be good for contracts attorneys if it ever gets to a review. Regulatory experts and antitrust attorneys reviewing the merger say it could be delayed by an antitrust review because of
Continue reading